Population PK and Semimechanistic PK/PD Modeling and Simulation of Relugolix Effects on Testosterone Suppression in Men with Prostate Cancer

Relugolix, the first orally active, nonpeptide gonadotropin‐releasing hormone receptor antagonist, is approved in the United States and the European Union for the treatment of adult patients with advanced prostate cancer. The recommended dosing regimen is a 360‐mg loading dose followed by a 120‐mg d...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Tien‐Yi, Pierrillas, Philippe Bernard, Lin, Yu‐Wei, de Greef, Rik, Zandvliet, Anthe Suzanne, Schindler, Emilie, Migoya, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091729/
https://www.ncbi.nlm.nih.gov/pubmed/36073238
http://dx.doi.org/10.1002/cpt.2743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091729/
https://www.ncbi.nlm.nih.gov/pubmed/36073238
http://dx.doi.org/10.1002/cpt.2743

Ejemplares similares